આંતરડાનું કેન્સર
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
ક્યાં જવું
આ ટ્રાયલ માટે ભારતમાં 8 હોસ્પિટલો દર્દીઓ લઈ રહી છે.
રજિસ્ટ્રી સમરી (ટેકનિકલ)
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectabl…
Sponsor: Janssen Research & Development, LLC
ClinicalTrials.gov પર NCT06750094
છેલ્લા 25 Sep 2026 ના રોજ અપડેટ થયું · અમે 20 Oct 2026 ના રોજ વાંચ્યું